{"product_id":"cy-pharm-pestle-analysis","title":"Challenge \u0026 Young PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a competitive edge with our targeted PESTLE Analysis of Challenge \u0026amp; Young—uncover how political, economic, social, technological, legal, and environmental forces are shaping its trajectory and your market moves; purchase the full report for actionable insights, data-driven risk forecasts, and ready-to-use slides and spreadsheets to power smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment healthcare spending policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSouth Korea's National Health Insurance, covering 97% of the population, tightly regulates drug pricing and reimbursement, directly constraining Challenge \u0026amp; Young's margin potential.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 the government increased fiscal scrutiny, targeting a 4–6% slowdown in pharmaceutical procurement growth to curb expenditures driven by a rapidly aging population (over-65s ~17.5%).\u003c\/p\u003e\n\u003cp\u003eChallenge \u0026amp; Young must align product pricing, value dossiers, and market-entry timelines with these budgetary priorities to secure and sustain reimbursement and market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug safety and quality initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe South Korean Ministry of Food and Drug Safety has accelerated efforts to cut medical errors via standardized drug labeling and distribution, citing a 2023 report showing medication-related adverse events at 1.4% of hospital admissions; this regulatory push favors Challenge \u0026amp; Young’s prescription-error reduction solutions. Political backing increases chances for government contracts—MOFDS budget for patient safety rose 12% to KRW 134 billion in 2024—so ongoing regulatory alignment is vital to secure institutional trust.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical trade stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe pharmaceutical supply chain in South Korea remains sensitive to regional trade tensions and global logistics disruptions; in 2024, Korea's pharmaceutical imports reached $14.2B, underscoring reliance on foreign APIs and finished products.\u003c\/p\u003e\n\u003cp\u003ePolicies promoting domestic self-sufficiency — including a 2025 government plan targeting a 30% rise in local API production by 2030 — favor local manufacturers like Challenge \u0026amp; Young.\u003c\/p\u003e\n\u003cp\u003eNavigating trade agreements is crucial for expansion into neighboring Asian markets, where Korea's bilateral deals cover over 70% of regional GDP, affecting tariffs and market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health infrastructure investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSignificant political capital is funding modernization of hospital information systems; WHO and World Bank-backed programs channeled over $12B globally for digital health in 2024–25, boosting demand for Challenge \u0026amp; Young’s specialized integration and cybersecurity services.\u003c\/p\u003e\n\u003cp\u003eStrategic partnerships with government-led digital health projects—such as national EHR rollouts covering 30–60% of hospitals in several countries—can lock in multi-year service contracts and create a durable competitive moat.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGlobal digital health funding ~ $12B (2024–25)\u003c\/li\u003e\n\u003cli\u003eNational EHR rollouts reach 30–60% hospital coverage\u003c\/li\u003e\n\u003cli\u003eCreates multi-year government contracts and integration demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical industry tax incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe South Korean government offers R\u0026amp;D tax credits up to 25% and cash grants via the Korea Drug Development Fund; in 2024 R\u0026amp;D tax expenditure reached KRW 9.6 trillion, supporting healthcare innovation.\u003c\/p\u003e\n\u003cp\u003eChallenge \u0026amp; Young can use these incentives to finance drug-usage optimization tech, lowering effective R\u0026amp;D costs and accelerating deployment.\u003c\/p\u003e\n\u003cp\u003eMonitoring corporate tax law shifts—effective tax rate was 22.5% in 2024 and proposed adjustments through 2026—remains critical to protect margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D tax credit up to 25%\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D tax expenditure: KRW 9.6 trillion\u003c\/li\u003e\n\u003cli\u003e2024 effective corporate tax rate: 22.5%\u003c\/li\u003e\n\u003cli\u003eLeverage grants (Korea Drug Development Fund) for tech funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKorean pharma: tight NHIS pricing, ageing demand, API push, plus R\u0026amp;D incentives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical factors constrain margins via NHIS pricing controls (covers 97%); fiscal tightening aims 4–6% slower pharma procurement by 2025 amid 17.5% over-65s; MOFDS patient-safety budget rose 12% to KRW 134B in 2024 favoring error-reduction solutions; policies target 30% increase in domestic API output by 2030; R\u0026amp;D tax credit up to 25%, 2024 R\u0026amp;D spend KRW 9.6T; corp tax ~22.5%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNHIS coverage\u003c\/td\u003e\n\u003ctd\u003e97%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOver-65s\u003c\/td\u003e\n\u003ctd\u003e17.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMOFDS safety budget 2024\u003c\/td\u003e\n\u003ctd\u003eKRW 134B (+12%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D tax credit\u003c\/td\u003e\n\u003ctd\u003eUp to 25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend 2024\u003c\/td\u003e\n\u003ctd\u003eKRW 9.6T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCorp tax rate 2024\u003c\/td\u003e\n\u003ctd\u003e22.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect the Challenge \u0026amp; Young across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with each section backed by current data and trends to identify threats, opportunities, and scenario-ready strategic insights for executives, consultants, and investors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise, visually segmented PESTLE snapshots that simplify external risk review for meetings and presentations, with editable notes for regional or business-line context and a shareable format ideal for quick team alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare cost containment trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cphospitals face mounting pressure to cut costs as u.s. adverse drug events cost an estimated billion annually and medication errors contribute deaths per year reducing waste malpractice payouts is a priority for administrators. challenge young solution targets prescription potentially lowering wastage at of hospital budgets exposure where average liability claims exceed by improving accuracy their service aligns with value-based care incentives cost-saving making it more compelling budget-conscious leaders.\u003e\n\u003c\/phospitals\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a South Korean pharmaceutical entity, exposure to KRW volatility versus USD, EUR and JPY matters: KRW weakened ~3.5% vs USD in 2024 and moved ±4% across 2023–2025, raising imported API costs by similar margins. Such swings can lift cost of goods sold and force price adjustments, compressing margins if FX pass-through is limited. Prioritizing FX hedging—for example forward contracts covering 60–80% of 12-month import flows—helps preserve competitiveness in domestic and export markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressure on manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising energy, labor and logistics costs lifted pharmaceutical manufacturing input costs by about 12–15% nationwide by end-2025, squeezing margins as Challenge \u0026amp; Young faces fixed NHS reimbursement rates; UK NHS drug price growth averaged under 2% in 2024–25. Implementing lean manufacturing and automation to trim waste and improve OEE by 5–10% is essential to offset higher COGS and protect net income.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of the private health sector\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe expansion of private clinics and specialized medical centers in South Korea created a secondary market for niche pharma services, with private healthcare spending rising to about KRW 45 trillion in 2023 (roughly USD 33 billion), representing ~22% of total healthcare expenditure.\u003c\/p\u003e\n\u003cp\u003eThese institutions often have more flexible procurement budgets than large public hospitals, enabling premium service offerings and higher margins for tailored products and services.\u003c\/p\u003e\n\u003cp\u003eTapping into this sector can diversify revenue streams and cut reliance on public tenders, where public hospital procurement accounted for over 60% of institutional drug purchases in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrivate healthcare spend KRW 45T (2023)\u003c\/li\u003e\n\u003cli\u003ePrivate share ~22% of total healthcare spend\u003c\/li\u003e\n\u003cli\u003ePublic procurement \u0026gt;60% of institutional drug purchases\u003c\/li\u003e\n\u003cli\u003eOpportunity: higher-margin, flexible contracts with clinics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvestment climate for biotech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eVenture and institutional funding in South Korea’s healthcare sector topped KRW 1.2 trillion in 2024, favoring firms with proven safety tech; Challenge \u0026amp; Young’s drug usage safety focus matches investor demand for ESG and sustainable health solutions.\u003c\/p\u003e\n\u003cp\u003eInvestors seek clear KPIs—revenue growth, CAC, and clinical validation—after 2023–24 biotech exits averaged 3.5x; sustained capital requires demonstrable financial performance and growth metrics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eKRW 1.2T VC\/institutional healthcare funding in 2024\u003c\/li\u003e\n\u003cli\u003e2023–24 biotech exit multiples ~3.5x\u003c\/li\u003e\n\u003cli\u003eInvestor focus: ESG, safety tech, clear KPIs\u003c\/li\u003e\n\u003cli\u003eNeed: revenue growth, CAC, clinical validation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising costs, FX pain squeeze hospitals—private clinics \u0026amp; safety-tech offer margin refuge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic pressure: drug-waste \u0026amp; malpractice costs (~$42B; 7,000 deaths\/year) drive hospitals to cut costs; FX volatility (KRW −3.5% vs USD in 2024) raises API COGS; energy\/labor up ~12–15% by end-2025 squeezes margins; private clinics (KRW 45T in 2023, ~22% share) offer higher-margin diversification; KRW healthcare VC KRW 1.2T (2024) favors safety-tech.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS adverse drug costs\u003c\/td\u003e\n\u003ctd\u003e$42B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKRW private healthcare (2023)\u003c\/td\u003e\n\u003ctd\u003eKRW 45T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX move (2024)\u003c\/td\u003e\n\u003ctd\u003eKRW −3.5% vs USD\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVC healthcare (2024)\u003c\/td\u003e\n\u003ctd\u003eKRW 1.2T\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eChallenge \u0026amp; Young PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Challenge \u0026amp; Young PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or teasers: the content, layout, and insights visible in this preview are the final file you’ll download immediately after payment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751546761593,"sku":"cy-pharm-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/cy-pharm-pestle-analysis.png?v=1772232866","url":"https:\/\/growthsharematrix.com\/products\/cy-pharm-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}